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The polypyrimidine tract-binding protein (PTB) is
an important regulator of alternative splicing. PTB-
regulated splicing of a-tropomyosin is enhanced by
Raver1, a protein with four PTB-Raver1 interacting
motifs (PRIs) that bind to the helical face of the
second RNA recognition motif (RRM2) in PTB. We
present the crystal structures of RRM2 in complex
with PRI3 and PRI4 from Raver1, which—along with
structure-based mutagenesis—reveal the molecular
basis of their differential binding. High-affinity bind-
ing by Raver1 PRI3 involves shape-matched apolar
contacts complementedbyspecifichydrogenbonds,
a newvariant of an establishedmodeof peptide-RRM
interaction. Our results refine the sequence of the PRI
motif and place important structural constraints on
functional models of PTB-Raver1 interactions. Our
analysis indicates that the observed Raver1-PTB
interaction is a general mode of binding that applies
to Raver1 complexes with PTB paralogues such as
nPTB and to complexes of Raver2 with PTB.
INTRODUCTION
Alternative splicing in metazoans produces multiple messenger
RNA (mRNA) transcripts from a single gene and is a powerful
mechanism for amplifying proteome complexity. Over 95% of
human multiexon genes have multiple splice isoforms (Nilsen
and Graveley, 2010). The process of pre-mRNA splicing involves
the controlled inclusion or exclusion of specific exons and is
regulated by cis-acting enhancer or silencer sequences found
either within the exon or within the flanking introns (Matlin
et al., 2005). The temporal and spatial control of splicing is also
determined by various positive and negative protein cofactors,
which are activated by developmental or differentiation-specific
cues.
One of the most intensively studied regulators of alternative
splicing is the polypyrimidine tract-binding protein (PTB). PTB
is a versatile protein. In addition to its nuclear splicing activity,1816 Structure 19, 1816–1825, December 7, 2011 ª2011 Elsevier LtdPTB is also found in the cytoplasm, where it has roles in the
stabilization and localization of mRNA (Ghetti et al., 1992; Cote
et al., 1999; Tillmar et al., 2002). It is also recruited to stimulate
translation initiation driven by internal ribosome entry sites
from cellular and viral mRNAs (Sawicka et al., 2008).
PTB is expressed in a variety of tissues (Patton et al., 1991) and
represses many muscle and neuron-specific exons, tissues in
which PTB levels are low (Xue et al., 2009; Llorian et al., 2010). It
has a number of tissue-specific paralogues in neurons (nPTB)
(Markovtsov et al., 2000; Polydorides et al., 2000), hematopoietic
cells (ROD1) (Yamamoto et al., 1999) and smooth muscle cells
(smPTB) (Gooding et al., 2003) which, with at least 50% amino
acid sequence identity, are closely related to the prototypical
protein. These paralogues appear to supplant or modulate the
programof splicing activity of PTB in the tissueswhere they occur
(Boutz et al., 2007; Makeyev et al., 2007).
Though best known as a negative regulator of splicing that
acts to exclude specific exons, PTB has recently been found
to determine exon inclusion in some cases (Xue et al., 2009;
Llorian et al., 2010). In common with a number of other splicing
regulators, its activity appears to be determined by the location
at which it binds to the RNA relative to the regulated exon (Witten
and Ule, 2011).
Several different mechanisms have been proposed for the
repressive splicing activity of PTB, including direct binding to
pre-mRNA in order to block binding of U2AF65—a component
of the spliceosome—to the polypyrimidine tract (Lin and Patton,
1995; Singh et al., 1995) or oligomeric assembly across exons to
mask splice sites (Wagner and Garcia-Blanco, 2001). In other
cases, PTB does not directly block splicing factor binding, but
rather the formation of splicing complexes across exons or
introns; these indirect mechanisms appear to result from the
ability of PTB to remodel pre-mRNA by bringing distal regions
of RNA into close proximity and so inducing looping (Chou
et al., 2000; Izquierdo et al., 2005; Cherny et al., 2010) or, as
has been shownmore recently, by bridging nonproductive asso-
ciation of pre-mRNA with stem-loop IV of U1 small nuclear RNA
(snRNA) (Sharma et al., 2008; Sharma et al., 2011). These mech-
anisms may all operate, depending on the particular pre-mRNA
being spliced, though part of the observed variety is likely a
reflection of the technical difficulty of studying splicing at the
molecular level.All rights reserved
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Figure 1. Structures of Raver1 PRIs Bound
to PTB RRM2
(A) Schematic diagrams of PTB, Raver1, and
Raver2 showing locations of RRMs and PRIs.
Residue numbers are indicated above each
protein.
(B) Comparison of the crystal structure of Raver1
PRI3 (green) bound to RRM2 (tan) with the NMR-
restrained docking model of the PRI3 peptide
(gray). The structures are shown schematically as
cartoon representations; the N and C termini of the
peptides are colored blue and red, respectively.
(C and D) Close-up views of the interactions of (C)
Raver1 PRI3 and (D) Raver1 PRI4 with PTB RRM2.
The Van der Waals surface of the RRM is depicted
as a semitransparent skin. All structural figures
were created using PyMOL (Delano, 2002). See
also Figure S1.
Structure
Structures of PTB-Raver1 ComplexesNevertheless, it is clear that PTB binds to both RNA and
proteins during splicing. The protein binds pyrimidine-rich
motifs within RNA (e.g., UCUU, CUCUCU), which are found in
regulatory elements (Pe´rez et al., 1997; Ray et al., 2009) that
may be structured (Clerte and Hall, 2009; Kafasla et al.,
2009). PTB binds RNA via b sheet surfaces on the four RNA
recognition motif domains (RRMs; Figure 1A) (Conte et al.,
2000; Simpson et al., 2004; Oberstrass et al., 2005) that are ar-
rayed in an elongated conformation (Petoukhov et al., 2006).
This arrangement allows multipoint contacts with RNA targets
that can remodel or stabilize RNA structures containing pyrim-
idine-rich motifs and offers a plausible basis for models of
PTB-mediated repression that invoke looping of pre-mRNA
(Oberstrass et al., 2005; Cherny et al., 2010; Lamichhane
et al., 2010) or contacts between pre-mRNA and U1 snRNA
(Sharma et al., 2011).
Splicing regulation by PTB or its paralogues also appears to
involve interactions with other regulatory proteins, including
Nova-1 and Nova-2 (Polydorides et al., 2000), Raver1 (Gromak
et al., 2003), and MRG15 (Luco et al., 2010). The best character-
ized of these is the PTB-Raver1 interaction, which modulates
splicing of a-tropomyosin (Tpm1). PTB acts to exclude themutu-
ally exclusive exon 3 of Tpm1 in smooth muscle cells but not in
other cells where PTB is expressed (Gooding et al., 1998). Over-
expression of PTB has little effect on this splicing event, suggest-
ing that it is not limiting. However, overexpression of Raver1
(Hu¨ttelmaier et al., 2001) causes a large increase in exon skip-
ping (Gromak et al., 2003).
Raver1, which is expressed in most tissue types, can be found
not only in the nucleus but also the cytoplasm, where it interactsStructure 19, 1816–1825, December 7, 2011 ªwith cytoskeletal proteins (Hu¨ttelmaier
et al., 2001). The protein has three
N-terminal RRMs—although only RRM1
has demonstrable, albeit weak, RNA-
binding activity (Lee et al., 2009)—and
an extended Pro-rich C terminus that
contains four conserved PTB-Raver1 in-
teractingmotifs (PRIs) with the consensus
sequence [S/G][I/L]LGxxP (Rideau et al.,
2006; Figure 1A). These motifs, whichare essential for Raver1 function, bind exclusively to the a-helical
side of the PTB RRM2 opposite the RNA-binding surface,
a mode of interaction that permits formation of ternary PTB-
RNA-Raver1 complexes. The initial analysis of PTB-Raver1 inter-
actions showed that only PRI1 and PRI3 bind with relatively high
affinity (Rideau et al., 2006). Raver2, which is a related protein of
unknown function, has a similar domain structure to Raver1:
three N-terminal RRMs and a Pro-rich C terminus (Figure 1A;
Kleinhenz et al., 2005). Although the C terminus is the least
well-conserved portion between the two proteins, Raver2 con-
tains two PRI motifs that are very similar to the PRI1 and PRI3
motifs found in Raver1 and have been shown also to mediate
binding to PTB (Henneberg et al., 2010).
The first structural analysis of the interaction of peptides
containing Raver1 PRI sequences with PTB only yielded a
nuclear magnetic resonance (NMR)-restrained docking model
because the affinity of purified PTB RRM2 for synthetic PRI3
peptides was too low for a full structure determination (Rideau
et al., 2006). Although it provides valuable insights, this model
is not precise enough to allow full dissection of the structural
basis of binding of Raver1 PRIs to PTB. By fusing Raver1
PRIs as N-terminal extensions to PTB RRM2, we have now ob-
tained crystal structures of PTB RRM2 complexed with Raver1
PRI3 and PRI4, which are high-affinity and low-affinity motifs,
respectively. In combination with mutagenesis, binding, and
splicing assays, these new structural data reveal a mode of
PTB-Raver1 interaction that is applicable to PTB paralogues
and other PRI-containing proteins and that places useful
constraints on models of the joint action of PTB and Raver
proteins.2011 Elsevier Ltd All rights reserved 1817
Table 1. Data Collection, Data Processing, and Refinement
Statistics for Crystal Structures of PRI3-RRM2 and PRI4-RRM2
PRI3-RRM2 PRI4-RRM2
Diffraction data
Space group C2 C2
a, b, c (A˚) 74.23, 60.60, 60.84 74.48, 60.38, 61.06
a, b, g () 90, 90, 107.51 90, 90, 107.86
Resolution range (A˚) 30.32-1.40
(1.48-1.40)
35.49-1.55
(1.63-1.55)
Reflections 50129 36156
Multiplicity 5.6 (5.3) 2.4 (2.4)
Completeness (%) 98.9 (96.1) 96.9 (96.5)
I/sI 15.4 (5.3) 10.2 (3.0)
Rmerge (%) 6.4 (35.4) 5.5 (35.8)
Refinement statistics
Rcalc (%) 22.3 21.6
Rfree (%) 23.1 22.1
Nonhydrogen atoms 1741 1723
Waters 191 132
Rms bond lengths (A˚) 0.005 0.005
Rms bond angles () 1.32 1.31
Ramachandran
(% favored/allowed)
98.0/1.4 97.7/2.3
PDB ID 3zzy 3zzz
Values in parentheses are for the highest resolution shell. PDB, Protein
Data Bank; Rms, root-mean-square.
Structure
Structures of PTB-Raver1 ComplexesRESULTS
Construct Design and Characterization
To determine the structure of a PTB-Raver1 complex, we over-
came the weak binding of short Raver1 peptides to PTB (Rideau
et al., 2006) by fusing the PRI3 sequence as an N-terminal exten-
sion of PTB RRM2 to increase the local concentration artificially,
a strategy that has worked for other protein-peptide complexes
(Candel et al., 2007). The PTB-Raver1 docking model indicated
that a linker of at least 20 amino acids would be required to
join the C-terminal end of the bound PRI3 peptide to the N
terminus of RRM2 (Rideau et al., 2006). The first chimeric
construct (PRI3-RRM2) was therefore designed to contain the
12-residue PRI3 sequence (PGVSLLGAPPKD—the conserved
core residues, which we number 1-7, are underlined) followed
by residues 156-285 of PTB RRM2. Residues 156-179 are
from the polypeptide that links RRM1 to RRM2 in the full-length
protein; residues 180-285 correspond to the structured RRM2
domain (Simpson et al., 2004; see Experimental Procedures).
The PRI3 sequence used in the chimera contains a Glu to Ala
mutation at position 5 in the core sequence, a carryover from
the previous NMR analysis, but this substitution does not affect
binding (Rideau et al., 2006).
The expression levels in E. coli and the solubility of the
PRI3-RRM2 chimera are much higher than for constructs
just containing RRM2 from PTB. PRI3-RRM2 is soluble to at
least 25 mg/ml, whereas recombinant RRM2 precipitates
above 6 mg/ml (Simpson et al., 2004). Although NMR analyses
and size-exclusion chromatography suggested that PRI3-
RRM2 exhibited concentration-dependent oligomerization (data
not shown) the fusion protein produced diffraction-quality
crystals. We therefore used the same strategy to fuse PRI1,
PRI2, and PRI4 of Raver1 and the PRI from hnRNP-L and
matrin-3 to PTB RRM2 (Figure 3D). All these constructs had
enhanced solubility similar to PRI3-RRM2, but only the con-
struct containing the low-affinity PRI4 (SSEGLLGLGPGP) also
crystallized.
Crystal Structures of PRI3-RRM2 and PRI4-RRM2
PRI3-RRM2 and PRI4-RRM2 crystals diffracted X-rays to 1.4 A˚
and 1.55 A˚, respectively. Diffraction data were phased by
molecular replacement using the NMR structure of PTB RRM2
(Simpson et al., 2004) as a search model. In each case, only
central portions of the PRI sequences were revealed by dif-
ference electron density maps (PRI3: VSLLGAPP; PRI4:
SEGLLGL) (see Figure S1 available online); there was no density
for the linker peptides connecting them to the RRM2 domain, so
these were not incorporated into the atomic models. Final
models for PRI3-RRM2 and PRI4-RRM2 were refined to Rfree
values of 23.1% and 22.1%, respectively (see Table 1 for full
statistics).
The crystals of PRI3-RRM2 and PRI4-RRM2 have two
complexes in the asymmetric unit that have almost identical
structures (e.g., for PRI3-RRM2, the all atom root-mean-square
deviation [rmsd] is 0.22 A˚; Figure S1B). Comparison of the RRM2
structures in each complex with the solution structures of PTB
RRM2 (rmsd = 1.0 A˚ over Ca atoms; Simpson et al., 2004; Ober-
strass et al., 2005) reveals no significant structural changes upon
peptide binding.1818 Structure 19, 1816–1825, December 7, 2011 ª2011 Elsevier LtdConformations of PRI3 and PRI4 Bound to PTB RRM2
The crystal structures of PRI3 and PRI4 from Raver1 in complex
with PTB RRM2 are consistent with many of the features found
in previous work: the peptides bind to the dorsal helical face of
the RRM domain and in the same orientation as determined by
NMR methods (Figure 1B) (Rideau et al., 2006). However, they
provide much more detailed information on the peptide-RRM
interaction and reveal previously undetected features of the
bound peptide. Strikingly, although our NMR-restrained docking
model assumed an extended conformation of the bound
peptide, the core peptides of PRI3 and PRI4 in the crystal struc-
tures adopt S-shaped conformations that wrap around the
peptide-binding surface on RRM2, which is formed by the a1
and a2 helices as well as the b1-a1 and a2-b4 loops (Figures
1C and 1D). Our earlier NMR docking model for the Raver1-
RRM2 complex was derived from eleven intermolecular NOEs
involving methyl groups and aromatic rings (Rideau et al.,
2006). All NOEs to Raver1 methyl groups are satisfied by the
crystal structure presented here, with the exception of the
A503, which is slightly farther away from the RRM domain than
in solution (Figure S2). This small difference is not unexpected,
as extensive conformational exchange was observed in NMR
spectra of bound Raver1 and likely reflects some averaging in
this region in solution.
There is an extensive bipartite hydrophobic interface between
the peptides and RRM2: the pair of Leu side chains at positions 2
and 3 in the motif both project into a shallow apolar depression
between the two helices on the dorsal face of RRM2, whereasAll rights reserved
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Figure 2. Detailed Structural Comparison of
Raver1 PRI3 and PRI4 Bound to PTB RRM2
(A and B) Close-up views of PRI3 bound to RRM2.
Intramolecular hydrogen bonds are shown as
orange dashes; intermolecular hydrogen bonds
are yellow.
(C and D) Equivalent views of PRI4 bound to
RRM2.
Structure
Structures of PTB-Raver1 Complexesdownstream residues of the PRIs are packed around the side
chains of Tyr 247 and Tyr 193, though in very different conforma-
tions for the two peptides (Figure 2). For PRI3, the four-residue
sequence 3LGAP6 wraps around Tyr 247 (Figure 2B), whereas
in PRI4 a different backbone conformation means that just three
residues, 3LGL5, are in contact with the tyrosine (Figure 2D).
Moreover, although in PRI3 Pro 6 and Pro 7 both contact the
side chains of Tyr 247 and Tyr 193, the equivalent residues in
PRI4 (Gly 6 and Pro 7) are not visible in the electron density
map, presumably due to disorder; this difference is likely to
contribute to the lower affinity of PRI4. The occlusion of hydro-
phobic features on the surface of RRM2 by the Raver1 peptide
probably accounts for the enhanced solubility of the chimeric
PRI-RRM2 proteins.
The observed hydrophobic contacts made by the Leu side
chains at positions 2 and 3 in the PRI explain why substitution
of either residue by smaller apolar residues is detrimental
to binding (Rideau et al., 2006). However, it is not clear why
a Leu-to-Ile substitution at position 2 in PRI3 has no effect,
whereas the same substitution at position 3 effectively abrogates
binding of the Raver1 PRI, especially since Leu 3 binds within
a shallower depression. Perhaps the branching at the Cb in Ile
introduces a steric clash that distorts nearby hydrogen bonds
between the Raver1 PRI3 and PTB RRM2.
In addition to the apolar contacts, there are specific hydrogen
bond interactions that contribute to PRI binding to PTB RRM2.
These show clear differences between PRI3 and PRI4, which
probably also contribute to the affinity differences between these
two motifs. In PRI3 (core sequence: SLLGAPP), Leu 2 and Leu 3
both project in the same direction into the binding pocket on PTB
RRM2 because of a pinched backbone conformation that is
stabilized by an internal hydrogen bond from the side-chain
hydroxyl of Ser 1 to the backbone amide of Gly 4 (Figure 2A).Structure 19, 1816–1825, December 7, 2011 ªIn this conformation, the peptide is able
to make four hydrogen bonds to PTB
RRM2.
In contrast, PRI4 (core sequence:
GLLGLGP) makes only three intermolec-
ular hydrogen bonds. The absence of
Ser at position 1 eliminates the intrapep-
tide hydrogen bond and results in a
more open backbone conformation. The
loss of this internal interaction allows the
peptide bond between Leu 3 and Gly 4
to flip with respect to PRI3, a conforma-
tional change that eliminates a hydrogen
bond to RRM2 (from the carbonyl group
of Gly 4; Figure 2C), which likely reduces
the affinity of this motif, although thepeptide flip is also needed to allow the 3LGL5 sequence to
wrap around Tyr 247.
Dissecting the Structural Basis of Differential PRI
Affinity
Previous work established that PRI1 and PRI3 bind with signifi-
cantly higher affinity than PRI2 and PRI4 (Rideau et al., 2006).
The new structural information suggests that the Leu 2-Leu 3
dipeptide found in both motifs is not sufficient for high-affinity
binding; instead, variations in amino acids at positions 1, 5,
and 6 appear to be crucial. To explore this idea, we introduced
mutations into PRI3 and PRI4 peptides (fused to MS2 proteins
at their C termini) and tested their effect on binding affinity in
pull-down assays (see Experimental Procedures).
Pro 6 of PRI3, which is conserved in the other high affinity
motif, PRI1, makes apolar contacts with Tyr 247 and Tyr 193
that are likely to contribute significantly to binding affinity.
This was confirmed by mutagenesis: although conservative
mutations of Pro 6 to Ala or Val—both of which retain the
apolar character of the side chain—only very slightly reduced
the affinity of PRI3 for PTB RRM2, substitution by a polar Ser
reduced binding 7-fold (Figure 3A). Thus, the presence of a
polar residue at position 6 within the PRI is detrimental to
binding, a result that is consistent with the low affinity of
Raver1 PRI2 and the PRI from hnRNP L, which have Ser
and His at this position, respectively (Rideau et al., 2006)
(Figure 3D).
To further explore the peptide features that affect binding to
PTB, we performed experiments to examine what changes
would be necessary to enhance the binding affinity of Raver1
PRI4. The structure shows that the presence of Gly 1 in PRI4
eliminates the internal stabilization of the backbone of PRI3
due to the hydrogen bond between Ser 1 and Gly 4 (Figures2011 Elsevier Ltd All rights reserved 1819
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Figure 3. Effect ofMutations of Raver1 PRIs
on Binding to GST-PTB
(A) Pull-down assays of binding of Raver1 PRI3
mutants to GST-PTB. Left: Loading controls
for 35S-Met-labeled PRI3-MS2 fusion proteins
containing PRI3 wild-type (WT) and the mutants
P6V, P6S, and P6A (see Experimental Proce-
dures). Right: Autoradiogram of PRI3-MS2 pro-
teins pulled down with GST (1 mg) or GST-PTB
(3 mg).
(B) Pull-down assays of binding of Raver1 PRI4
mutants to GST-PTB. Left: Loading controls
for 35S-Met-labeled PRI4-MS2 fusion proteins.
Right: GST pull-down of PRI4 constructs with
GST (5 mg) or GST-PTB (15 mg). Although PRI4
constructs migrate as a doublet (as observed
previously [Rideau et al., 2006]), both products of
the in vitro transcription-translation reaction
contain the PRI since they bind PTB with the same
affinity.
(C) Comparison of binding of wild-type andmutant
Raver1 PRIs to GST-PTB. Left: Loading controls.
Right: GST pull-down of PRI4 constructs with GST
(2 mg) or GST-PTB (6 mg).
(D) PRI sequences from murine Raver1
(AAP33691), murine Raver2 (NP_898845), human
matrin-3 (NP_001181884), and human hnRNP-L
(NM_001533). Sequences shown for Raver1 are
the 20 amino peptides used in pull-down assays;
the shaded box indicates the sequences included
in PRI-RRM2 chimeras for structural studies.
Sequence similarity and identity within the PRI
core are indicated. Residues in Raver1 PRI3 and
PRI4 that were tested by mutagenesis are in
boldface. See also Figure S3.
Structure
Structures of PTB-Raver1 Complexes2A and 2C). However, this interaction seems to have little
effect on the affinity for RRM2, because substitution of Gly 1
by Ser in PRI4 only increased the binding 1.7-fold (Figure 3B),
consistent with the observation that Gly occurs at position 1
in the high-affinity PRI1 sequence (Figure 3D). In contrast,
there was a stronger 4-fold enhancement of binding when
the double mutation Leu5Ala/Gly6Pro was used to convert
the 3LGLGP7 sequence in PRI4 to the 3LGAPP7 found in our
modified version of the high-affinity PRI3 and in PRI1 (Fig-
ure 3B). Together these observations suggest that interaction
of Pro 6 with the tyrosine pocket in PTB RRM2 is essential
for a high-affinity interaction with PTB, whereas the backbone
stabilization due to Ser 1 plays a minor supporting role. More-
over, the mutagenesis results help to verify the functional rele-
vance of the structures obtained from our artificial chimeric
constructs.
Intriguingly, the L5A/G6P substitutions in PRI4 make its core
sequence identical to that of PRI1 (Figure 3D), but this mutant
binds approximately 10-fold less well to GST-PTB than PRI1
(Figure 3C). This suggests that elements outside the conserved
core motif of Raver1 may play a role in binding to PTB.
However, although the 20-residue peptide sequence used in
the binding assays is longer than the 12-residue sequence
incorporated into the chimeric constructs used for crystal-
lization, comparison of the flanking sequences (Figure 3D)1820 Structure 19, 1816–1825, December 7, 2011 ª2011 Elsevier Ltdreveals no obvious patterns of conservation that correlate
with binding.
Interactions of Raver1 PRIs with nPTB
To identify whether the mode of binding of Raver1 PRI peptides
to PTB is the same in other PTB paralogues, we investigated their
binding to GST-nPTB in pull-down assays. The sequence iden-
tity between PTB and nPTB is over 74% (Markovtsov et al.,
2000; Polydorides et al., 2000). Mapping of the RRM2 sequence
differences between PTB and nPTB onto the structure reveals
that they cluster in two distinct regions. One group is located
on the upper surface of helix a2, quite separate from the PRI
binding site, whereas a second smaller cluster occurs on the
b1-a1 loop, which, together with the adjacent a2-b4 loop, forms
part of the Raver1 binding surface (Figure S3A). Despite these
differences, binding assays revealed that the relative affinities
of PRIs 1-4 for PTB and nPTB are very similar. Thus, PRI1 and
PRI3 bind strongly to both paralogues, whereas PRI2 and PRI4
have much weaker affinity (Figure S3C). Furthermore, mutations
designed to reduce or enhance the affinities of PRI3 and PRI4 for
PTB RRM2 had similar effects on their binding to nPTB: the P6S
mutation in PRI3 P6S reduced binding for nPTB, whereas the
binding PRI4 L5A/G6P was enhanced (compare Figure S3C
with Figure 3). These observations support the contention that
PTB and nPTB interact with Raver1 PRIs in the same way.All rights reserved
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Figure 4. Mutation of PTB RRM2 RNA and PRI Interacting Surfaces
Impairs Activity
(A) Effects of RRM2 mutations on an MS2-tethered splicing regulation assay.
The Tpm1 exon 1-3-4 splicing reporter, with the PTB site downstream of exon
3 replaced by a pair of MS2 coat protein binding sites, was transfected into
HeLa cells, and splicing patterns were analyzed by RT-PCR. Lane 1: reporter
alone. Lane 2: reporter cotransfected with MS2 coat protein. Lanes 3-6:
reporter cotransfected with MS2-PTB2L expression constructs (wild-type
[WT], Y247Q, K271A, K266A/Y267A/K271A, respectively). Percent exon
skipping (±SD) is shown below each lane.
(B) Western blots to show equivalence of expression of MS2-PTB2L tested in
panel A (anti-FLAG). Loading control, anti-actin.
(C) Electrophoretic mobility shift assay of 0.2-3.2 mM recombinant PTB RRM2
wild-type (lanes 2-6), K271A (lanes 7-11), and Y247Q (lanes 12-16). Lane 1: no
protein.
(D) Pull-down of in vitro translated full-length Raver1 with the indicated
GST-fusion proteins.
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Structures of PTB-Raver1 ComplexesPTB Mutations Affect PRI Binding and Activity
To extend our understanding of the PTB-Raver1 interaction, we
generated PTB RRM2 mutants and tested them for binding of
Raver1 and RNA and for their ability to regulate splicing of Tpm1.
PTB RRM2, along with the following inter-RRM linker (PTB 2L),
was previously shown to be fully active as a splicing repressor
domain when fused to MS2 coat protein and tethered to Tpm1
RNA by an MS2 binding site, which replaced the natural down-
stream PTB binding site (Robinson and Smith, 2006). We there-
fore used this tethered repressor domain assay to test the effects
of mutations designed to target the PTB-Raver1 interaction. Co-
transfection of the splicing reporter construct with an MS2
expression vector had no effect on the low basal level of exon
skipping (Figure 4A, lanes 1,2), while transfection of wild-type
PTB 2L-MS2 led to 61% exon skipping (lane 3). Mutations of
Tyr 193, Leu 241, and Gln 244 had no effect (data not shown).
However, mutation of Tyr 247 to Gln reduced activity by a third
(Figures 4A, lane 4). This reduction in activity is consistent with
the close contacts made by Tyr 247 with hydrophobic side
chains in each of the PRIs (Figures 2B and 2D). As a control,
we also tested the effects of mutations on the RNA-binding
surface of RRM2 (K271A and K266A/Y267A/K271A), which are
predicted to have no effect on PRI binding. Both single and triple
RNA binding mutations severely impaired the splicing repressor
activity (Figures 4A and 4B). To confirm the specificity of the
mutations, recombinant GST-PTB RRM2 proteins were tested
for the ability to pull down in vitro-translated Raver1 protein (Fig-
ure 4D) and to bind to RNA (Figure 4C). As expected, the Y247Q
mutant showed complete impairment of Raver1 interaction (Fig-
ure 4D; compare to GST-Sxl nonspecific control), but bound to
RNA comparably to wild-type RRM2. In contrast, the K271A
mutant was impaired for RNAbinding but interactedwith Raver1.
These observations are consistent with the previous finding that
PTB RRM2 can form a ternary complex with the Raver1 PRI and
a short RNA oligomer (Rideau et al., 2006), and confirm the inde-
pendence of the two interacting surfaces of RRM2. Moreover, it
is interesting to note that, given that RRM1 and RRM2 of PTB
have been shown to interact with U1 stem-loop IV (Sharma
et al., 2011), the strong effect of the RNA-binding mutations in
PTB 2L-MS2 on repression of Tpm1 exon 3 (Figure 4) may be
due to impairment of binding to U1 snRNA.
DISCUSSION
In this report, we present, to our knowledge, the first structural
analysis of a PTB-protein complex involved in splicing: the
crystal structures of PTB RRM2 in complex with two peptide
motifs from Raver1, the protein recruited to corepress exon 3
of Tpm1. Though the structures contain only a single domain
of PTB, this is the major structured portion of PTB-2L, the min-
imal fragment required to recapitulate the activity of the full-
length protein in exon exclusion (Robinson and Smith, 2006)
and, as has been shown more recently, inclusion (Xue et al.,
2009; Llorian et al., 2010).
Analysis of the structure and RNA-binding properties of PTB
have helped to inform ideas about how PTB works, first by delin-
eating the unexpected architecture of the domains and so paving
the way for more precise functional studies using structure-
based mutagenesis (Conte et al., 2000; Simpson et al., 2004;Structure 19, 1816–1825, December 7, 2011 ª2011 Elsevier Ltd All rights reserved 1821
Raver1  
PRI 3 
eIF3J 
SF3b155 
U2AF65 
PTB  
RRM2 
Figure 5. Comparison of the PTB-Raver1 Interaction with Other
Peptide-RRM Complexes
A common mode of binding is revealed by superposition of the complex
of Raver1 PRI3 and PTB RRM2 with the peptide/RRM complexes of U2AF65/
U2AF35 (PDB-1jmt), SF3b155/SPF45 (PDB-2peh) and eIF3j/eIF3b (PDB-
2krb). PTB RRM2 is colored tan; other RRMs are colored gray. The superpo-
sition was performed for the RRM domains using PyMOL (Delano, 2002). See
also Figure S4.
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Structures of PTB-Raver1 ComplexesOberstrass et al., 2005), then by revealing modes of RNA
binding, which led to testable suggestions of how binding of
PTB might remodel RNA to affect splicing (Oberstrass et al.,
2005; Petoukhov et al., 2006; Lamichhane et al., 2010).
Our growing understanding of PTB-RNA interactions has influ-
enced models of PTB-mediated exon repression, its best-char-
acterized activity. Several plausible mechanisms have emerged,
built on the observation that PTB molecules are involved at
multiple binding sites in pre-mRNA located within or near to
regulated exons. Possible modes of repression include masking
of splicing signals by direct contact (Singh et al., 1995; Wagner
and Garcia-Blanco, 2001) or PTB-mediated looping (Chou
et al., 2000; Oberstrass et al., 2005; Cherny et al., 2010; Lamich-
hane et al., 2010; Llorian et al., 2010); additionally or alternatively,
PTB may interfere with spliceosome assembly by binding to
stem-loop IV of U1 snRNA (Sharma et al., 2011).
Less attention has been paid to the interactions that PTB
makes with other proteins to regulate splicing (or indeed, any
other PTB-mediated activity), despite observations of PTB-
binding partners that have accumulated over the past 10 years
and now include not only Raver1 and Raver2 (Hu¨ttelmaier
et al., 2001; Henneberg et al., 2010), but also Nova-1 and
Nova-2 (Polydorides et al., 2000) and, possibly, MRG15 (Luco
et al., 2010). Clearly delineation of the details of PTB-protein
interactions is important for a more complete understanding of
the molecular mechanism of splicing regulation.
The crystal structures of PTB RRM2 in complex with Raver1
reveals a mode of peptide binding that has been observed in
other RRM-peptide complexes such as U2AF35/U2AF65 (Kiel-
kopf et al., 2001), SPF45/SF3b155 (Corsini et al., 2007), and
eIF3b/eIF3j (Elantak et al., 2010): the peptide binds in an orienta-
tion that is broadly perpendicular to the two helices on the dorsal
surface of the RRM (Figure 5). The REF/ICP27 complex, in which
the peptide lies parallel to the helices, is a notable exception
(Tunnicliffe et al., 2011; Figure S4).
Nevertheless, the PTB-Raver1 complex marks an interesting
variation on this theme. Although in the three examples of
perpendicular binding mentioned above peptide binding is
anchored by insertion of a Trp side chain from the peptide into
a deep apolar pocket between the helices on the RRM, in the
Raver1 peptide the role of this Trp is taken by a pair of Leu
side chains that insert into a shallower hydrophobic depression
in a similar location on the RRM. This pair of Leu side chains
make important hydrophobic contacts that contribute to binding
of Raver1 PRIs to PTB RRM2; however, they are not sufficient
for high-affinity binding, because this sequence feature is also
found in PRI2 and PRI4, which have lower affinity (Rideau
et al., 2006). Additional interactions are also important for tight
binding. The PRI3-RRM2 complex reveals that these interactions
include a number of specific hydrogen bonds—mostly between
main-chain groups—and the interaction of the Pro-Pro dipeptide
at positions 6 and 7 in themotif with the Tyr pocket formed by Tyr
247 and Tyr 193 (Figure 2B). Although PRI4 exhibits an alterna-
tive mode of binding, which inserts a hydrophobic Leu side chain
(from position 5 of the motif) within this Tyr pocket, this is insuf-
ficient for high-affinity binding (Figure 3C). Moreover, mutagen-
esis experiments show that substitution of the Pro at position 6
in the PRI3 motif with a polar residue (such as Ser) is sufficient
to impair binding (Figure 3A), a result that accounts for the low1822 Structure 19, 1816–1825, December 7, 2011 ª2011 Elsevier Ltdaffinity observed for the PRI2 sequence of Raver1 (Rideau
et al., 2006). The overall mix of interactions observed echoes
similar observations from other structures of RRM-peptide
complexes such as U2AF35/U2AF65 (Kielkopf et al., 2001) and
SPF45/SF3b155 (Corsini et al., 2007).
Given the close sequence similarity between the PRI1 and
PRI3 motifs from Raver1, the structural and binding data pre-
sented here offer a plausible explanation for the high affinity of
PRI1 and suggest strongly that it binds to PTB RRM2 in the
same way. The same can probably also be said of the two
high-affinity PRI motifs in Raver2, which are similar to Raver1
PRI1 and PRI3 (Henneberg et al., 2010; Figure 3D).
We have also shown that despite a cluster of sequence differ-
ences between PTB and its neuronal paralogue near the Raver1-
binding site on RRM2, nPTB exhibits a very similar pattern of
variation of affinity for the Raver1 PRIs (Figure S3). The Raver1
binding site is therefore common to both these paralogues,
and it will be worth investigating whether this function is retained
by other PTB paralogues such as ROD1 (Yamamoto et al., 1999;
Hu¨ttelmaier et al., 2001) and smPTB (Gooding et al., 2003).
Furthermore, the results allow us to refine the definition of what
constitutes a high-affinity PRI sequence from [S/G][I/L]LGxxP to
[S/G][I/L]LGxFP,where theF at position 6 indicates a preference
for a small hydrophobic residue (Pro, Val, Ala). Using Scan-
Prosite (de Castro et al., 2006), 36 human proteins can be
identified that contain predicted high-affinity PRIs conforming
to [S/G][I/L]LGx[AVP]P, including Raver1 and Raver2, each of
which contain two sites. The nuclear matrix protein matrin-3
contains the motif GILGPPP, which is necessary and sufficient
for interaction with PTB (M.C. and C.W.J.S., unpublished data).
In addition, the 30 end processing factors CSTF2 and CSTF2T
both contain the motif GLLGDAP suggesting a molecular basisAll rights reserved
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(Castelo-Branco et al., 2004). Other potential PRI containing
proteins such as the deacetylase HDAC6 and a histone deme-
thylase, JMJD8, hint at further interesting and functionally
diverse targets of PTB.
The PTB-Raver1 complexes presented here place constraints
on possible modes of corepression by PTB and Raver1.
Although there are four PTB-binding motifs in the C-terminal
region of Raver1, each appears capable of only binding to a
single molecule of PTB. The stoichiometry of PTB-Raver1 com-
plexes that assemble on regulated exons could therefore be 2:1,
if only high-affinity sites are engaged. However, it remains
possible that low-affinity sites may also contribute to binding,
not least because tethering of Raver1 to PTB via the two high-
affinity sites will augment the local concentration of PRIs. This
would be consistent with the model envisaged by Cherny et al.
(2010) on the basis of their observations of multiple PTB mole-
cules binding in the vicinity of regulated exons in Tpm1. Against
this, however, it is has been observed that mutation of a single
PRI3 motif in Raver1—and of an identical PRI in Raver2 (PRIb
in Figure 3D)—was sufficient to abrogate binding to PTB and
PTB-mediated localization to perinucleolar comparments in
HeLa cells (Henneberg et al., 2010). Although this may point to
a 1:1 stoichiometry for PTB-Raver1 complexes, it remains true
that mutation of other high-affinity PRIs in Raver1 or Raver2
significantly reduces binding to PTB (Rideau et al., 2006; Henne-
berg et al., 2010). The full details of functional PTB-Raver1 inter-
actions have yet to be worked out. It is interesting to note the
similar spacing between the high-affinity PRIs in Raver1 and
Raver2 (approximately 135 amino acids; see Figure 1A), which
perhaps points to a common architecture of functional PTB-
Raver complexes.
EXPERIMENTAL PROCEDURES
Plasmid Construction
For structural analysis, PRI-RRM2 chimera constructs containing residues
156-285 of PTB were generated by PCR using PTB1 complementary DNA
as a template (Gil et al., 1991). The forward primer incorporated an NcoI site
and sequences coding for 12 amino acids from the PRI sequences (from
Raver1, hnRNP-L, and matrin-3), whereas the reverse primer introduced a
stop codon and downstream HindIII site. The resulting PCR product was
ligated into the pETM-11 vector, which adds a TEVpro-cleavable N-terminal
6xHis tag (Zou et al., 2003).
For pull-down experiments, we used Quikchange (Stratagene) to mutate
MS2-Raver1 fusion proteins that were made previously (Rideau et al., 2006).
These incorporate 20-residue Raver1 PRI sequences as N-terminal exten-
sions. Plasmids for GST-PTB (Gromak et al., 2003) and GST-nPTB—a gift
from B.J. Blencowe—(Calarco et al., 2009) have been described. All plasmids
were sequenced by MWG Eurofins Ltd.
Protein Expression and Purification
PTB proteins were expressed at 37C in E. coli BL21 (DE3). Cell pellets were
lysed by sonication in Buffer A (250 mM NaCl, 25 mM Tris [pH 7.8]), 0.1% (v/v)
Triton X-100, and 0.5 mM phenylmethanesulfonylfluoride containing 1 mg/ml
lysozyme. 6xHis-tagged proteins were purified from clarified lysates using
TALON resin (Clontech). Purified proteins were eluted in Buffer A containing
100 mM imidazole. The 6xHis tag was removed by overnight incubation at 4C
with 1 mg of his-tagged TEVpro per 30 mg of PRI-RRM2 during dialysis against
Buffer A with 5 mM b-mercaptoethanol. The cleaved tag and TEVpro were
removed in a second round of TALON purification. For crystallization, proteins
were further purified by gel filtration on a Superdex 75 16/60 column (GEHealth-
care) in 100 mM NaCl, 25 mM Tris (pH 7.8), and 1 mM dithiothreitol (DTT).Structure 19, 1816–18For pull-down assays to monitor Raver1 binding, glutathione S-transferase
(GST) tagged PTB proteins were extracted from E. coli in a similar manner and
applied a glutathione sepharose 4B column (GE Healthcare). The column was
washed with Buffer A and proteins were eluted in Buffer A + 5 mM DTT and
20 mM glutathione (pH 9.0). Purified proteins were concentrated by centrif-
ugal filtration to 22 mg/ml, 28 mg/ml, 5.5 mg/ml, and 4.3 mg/ml for PRI3-
RRM2, PRI4-RRM2, GST-PTB, and GST-nPTB, respectively and stored
at 80C.
GST-PTB RRM2 fusion proteins used in Figure 4 were PCR amplified and
cloned into the EcoRI site in pGEX3 (to incorporate residues 181-284). Cells
were lysed by passing twice through a French press in MTPBS buffer
(150mMNaCl, 16mMNaH2PO4, 1mMDTT, 3mMPMSF, EDTA-free protease
cocktail [Roche]). Soluble and insoluble fractions were separated by centrifu-
gation at 8,000 g for 10 min. GST fusion proteins were purified through a gluta-
thione sepharose 4B column (GE Healthcare), washed with MTPBS + 1%
Triton X-100, and step-eluted using reduced glutathione. Protein-containing
fractions were dialyzed in Buffer E (20 mM HEPES, 100 mM KCl, 3 mM
MgCl2, 0.1 mM EDTA, 1 mM DTT, 20% glycerol, 0.05% Nonidet-P40). The
GST-PTB and GST-SXL proteins used as a control in Figure 4D were prepared
as described (Rideau et al., 2006).
Structure Determination
Purified recombinant PRI-RRM2 proteins at 18 mg/ml were crystallized by
sitting drop vapor diffusion using a reservoir solution containing 0.2 M NaI,
0.1 M Bis-Trispropane (pH 6.5), and 20% polyethylene glycol 3350. Crystals
were soaked for 1 min in mother liquor with 20% glycerol before flash
freezing in liquid N2. X-ray diffraction data were collected at beamlines
X13 at DESY, Hamburg, Germany, and I02 at Diamond Light Source, Didcot,
UK. The data were processed with iMosfilm and scaled using SCALA from
the CCP4 suite (Collaborative Computational Project, No. 4, 1994). PRI3-
RRM2 data were phased by molecular replacement with Phaser v1.2
(McCoy et al., 2007) using the ensemble of NMR structures of PTB RRM2
as a search model (Simpson et al., 2004). PRI4-RRM2 was phased by rigid
body refinement using the RRM2 domain from the refined PRI3-RRM2 struc-
ture since the two chimeric proteins crystallized isomorphously. Models were
manually adjusted in O (Jones et al., 1991) and refined with CNS (Bru¨nger
et al., 1998).
Pull-Down Assays
In vitro GST pull-down assays were performed essentially as described in
(Gromak et al., 2003). Briefly, 35S-Met-labeled MS2-Raver1 proteins produced
by in vitro transcription-translation reactions (TNT Quick Coupled System,
Promega) were incubated for 3 hr at 4C with GST, GST-PTB, or GST-nPTB
in wash buffer (100 mM KCl, 20 mM HEPES [pH 7.9], 0.5 mM DTT, 0.2%
Tween-20, and 10% glycerol) in the presence of 5 ml glutathione sepharose
4B. Beads were then washed three times with wash buffer, and bound protein
was eluted using SDS loading buffer for SDS-PAGE analysis. Protein band
intensities on dried gels were recorded using a Fuji FLA-5000 phosphor
imager; quantitative densitometry was performed using AIDA software
(Raytest).
Electrophoretic Mobility Shift Assays
GST-PTB RRM2 proteins (0.2-3.2 mM) were incubated with 10 fmol of an RNA
probe spanning the Tpm1 exon 3 polypyrimidine tract, which is enriched in
PTB binding sites (Cherny et al., 2010) in 10 mM HEPES, 100 mM KCl,
3 mMMgCl2, 5% glycerol, 1 mM DTT, 0.25 mg of E. coli rRNA, RNase inhibitor
(DCP) for 30 min at 30C and loaded directly onto a 5% polyacrylamide
(40:1) gel.
Splicing Assays
Splicing transfection assays were carried out as described previously (Robin-
son and Smith, 2006). Briefly, 200 ng of the splicing reporter and 800 ng of
effector DNA were transfected into HeLa cells in 35-mm wells, followed by
RT-PCR analysis of the splicing products 48 hr after transfection (Robinson
and Smith, 2006). The splicing reporter pT2Dbp-2MS2 is a modified version
of TM-2MS2 (Robinson and Smith, 2006) containing a mutation of the canon-
ical branch-point of the Tpm1 exon 3, which leads to enhanced exon skipping
in HeLa cells (Gooding et al., 2006).25, December 7, 2011 ª2011 Elsevier Ltd All rights reserved 1823
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